29 3月 2018 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2017 Financial Results
29 3月 2018 by admin in UncategorizedComments ARMO BioSciences Enrolls First Patient in the CYPRESS 2 Trial Evaluating AM0010 in Non-Small Cell Lung Cancer
28 3月 2018 by admin in UncategorizedComments Tempest Therapeutics Closes $70 Million Series B Financing – Cancer immunology programs launched from Versant’s Inception Discovery Engine –
26 3月 2018 by admin in UncategorizedComments ARMO BioSciences Announces Positive Outcome of First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study
19 3月 2018 by admin in UncategorizedComments resTORbio Announces Formation of Clinical Advisory Board
12 3月 2018 by admin in UncategorizedComments Syros Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
01 3月 2018 by admin in UncategorizedComments Centrexion Therapeutics to Present CNTX-4975 Clinical Data at the American Academy of Orthopaedic Surgeons 2018 Annual Meeting
21 2月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces First Patient Dosed in Phase 3 Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
07 2月 2018 by admin in UncategorizedComments Syros Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
30 1月 2018 by admin in UncategorizedComments resTORbio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
25 1月 2018 by admin in UncategorizedComments ARMO BioSciences Announces Pricing of Initial Public Offering
16 1月 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Fast Track Designation Granted by FDA to CNTX-4975 for Treatment of Knee Osteoarthritis Pain
03 1月 2018 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
02 1月 2018 by admin in UncategorizedComments Centrexion Therapeutics Raises $67 Million; Launching Phase 3 Program for CNTX-4975 in Knee Osteoarthritis Pain in 2018
30 11月 2017 by admin in UncategorizedComments resTORbio Raises $40 Million to Advance Selective TORC1 Inhibitors for Aging-Related Diseases and Conditions
11 11月 2017 by admin in UncategorizedComments How Quan Plans To Deploy Its Inaugural $150m Healthcare Fund
29 8月 2017 by admin in UncategorizedComments ARMO BioSciences Raises $67 Million in a Series C-1 Financing
